Rentosertib clinical trials
Also written INS018_055.
How each study uses rentosertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rentosertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- INS018_055
- 3
Studies by the year they started
4 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
InSilico Medicine Hong Kong Limited (4)
Studies
Open first, then newest update. How each study uses rentosertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingPhase 3InSilico Medicine Hong Kong LimitedNCT07687459Written as INS018_055 tablets
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary FibrosisRecruitingPhase 2InSilico Medicine Hong Kong LimitedNCT05975983Written as INS018_055
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedPhase 2InSilico Medicine Hong Kong LimitedNCT05938920Written as INS018_055
- A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy SubjectsCompletedPhase 1InSilico Medicine Hong Kong LimitedNCT05154240Written as INS018_055
Codes
What other systems call rentosertib · ClinicalTrials.gg INT017275
- UNII (FDA) M9NU5G8WXYRENTOSERTIBConfirmed FDA, Wikidata
- Wikidata Q135642220rentosertibConfirmed FDA, Wikidata
- NCI Thesaurus C221003RentosertibOne source FDA
- DrugBank DB18083One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M9NU5G8WXY | RENTOSERTIB | Confirmed FDA, Wikidata |
| Wikidata | Q135642220 | rentosertib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C221003 | Rentosertib | One source FDA |
| DrugBank | DB18083 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.